These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12077721)

  • 21. Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?
    De T; Park CS; Perera MA
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():577-603. PubMed ID: 30296897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
    Božina N; Vrkić Kirhmajer M; Šimičević L; Ganoci L; Mirošević Skvrce N; Klarica Domjanović I; Merćep I
    Croat Med J; 2020 Apr; 61(2):147-158. PubMed ID: 32378381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).
    Lamoureux F; Duflot T;
    Therapie; 2017 Apr; 72(2):257-267. PubMed ID: 28237404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.
    Berinstein E; Levy A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging clinical applications in cardiovascular pharmacogenomics.
    Damani SB; Topol EJ
    Wiley Interdiscip Rev Syst Biol Med; 2011; 3(2):206-15. PubMed ID: 20730785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Implementation of Cardiovascular Pharmacogenomics.
    Pereira NL; Stewart AK
    Mayo Clin Proc; 2015 Jun; 90(6):701-4. PubMed ID: 26046404
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiovascular pharmacogenetics.
    Myburgh R; Hochfeld WE; Dodgen TM; Ker J; Pepper MS
    Pharmacol Ther; 2012 Mar; 133(3):280-90. PubMed ID: 22123178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomics in cardiovascular diseases.
    Mukherjee D; Topol EJ
    Curr Probl Cardiol; 2003 May; 28(5):317-47. PubMed ID: 14614445
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists.
    Würtz M; Lordkipanidzé M; Grove EL
    J Thromb Haemost; 2013 Sep; 11(9):1627-39. PubMed ID: 23809178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacogenomics: the quest for individualized therapy].
    López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
    Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics in cardiovascular antithrombotic therapy.
    Marín F; González-Conejero R; Capranzano P; Bass TA; Roldán V; Angiolillo DJ
    J Am Coll Cardiol; 2009 Sep; 54(12):1041-57. PubMed ID: 19744613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care.
    Rusnak JM; Kisabeth RM; Herbert DP; McNeil DM
    Mayo Clin Proc; 2001 Mar; 76(3):299-309. PubMed ID: 11243277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics and management of cardiovascular disease.
    Howe LA
    Nurse Pract; 2009 Aug; 34(8):28-35; quiz 36. PubMed ID: 19638892
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?
    Roden DM
    Can J Cardiol; 2013 Jan; 29(1):58-66. PubMed ID: 23200096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics/genomics and personalized medicine.
    Sadée W; Dai Z
    Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R207-14. PubMed ID: 16244319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiovascular pharmacogenomics].
    Ahlehoff O; Hansen PR
    Ugeskr Laeger; 2009 Apr; 171(17):1405-7. PubMed ID: 19413939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Genetic biomarkers and personalized medicine: application in cardiovascular pharmacology].
    Carrillo Norte JA
    Rev Enferm; 2013 Jan; 36(1):41-50. PubMed ID: 23427736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics.
    Johnson JA; Terra SG
    Pharm Res; 2002 Dec; 19(12):1779-87. PubMed ID: 12523655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine.
    Nakagawa K; Ishizaki T
    Pharmacol Ther; 2000 Apr; 86(1):1-28. PubMed ID: 10760544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.